Chewy reported $3.33 billion in quarterly sales, beat its own forecasts, and raised its guidance for the year. Then its stock dropped 11% in a single day. Morgan Stanley, which reviewed the results in a note it shared with TheStreet on September 9, thinks the sell-off was an overreaction. But the firm also coined a phrase that tells you everything about the real problem: "treat-cession."

That word is worth sitting with for a moment. A treat-cession is not a recession. Nobody's pet is going hungry. What's happening is subtler and, in some ways, more telling about where American household budgets are right now.

The loyal customer is still there. She's just buying less.

Chewy built its business on subscription-style repeat purchases. Pet owners sign up, and food, medicine, and supplies show up at the door automatically. That model created one of the stickiest customer bases in retail. But sticky is not the same as immune to financial pressure.

The Covid pandemic sent pet adoptions soaring, and spending followed. Pet products were one of the strongest consumer categories from 2020 to 2022, according to the American Pet Products Association. That wave has now receded, and it's running into a second headwind: the rising cost of everything else. Food, housing, utilities. When the essentials get more expensive, the dog treats get smaller or less frequent, even if the dog doesn't.

Morgan Stanley's read is that Chewy's organic growth, stripping out the revenue added by two recent acquisitions, has stabilized at roughly 6% year over year. That's the company's actual baseline, the analysts say, under current conditions. It is not collapsing. But it is not accelerating either.

The surface-level numbers in Chewy's second-quarter report looked better than that stabilization suggests. Revenue grew 7.3% compared to the same period last year. But roughly $100 million of that came from the April 2026 acquisition of Modern Animal, a veterinary platform, and another $80 million from SmartPak, an equine health brand acquired in late 2025. Take those out, and underlying growth slowed by about 1.2 percentage points from the previous quarter.

The profit beat had a similar asterisk. About $15 million of the operating profit figure came from one-time items that won't repeat. Strip those out, and the midpoint of Chewy's full-year profit guidance actually edged slightly lower. Stock-based compensation jumped 17% in a single quarter, which gives skeptics a reason to question whether the earnings picture is as clean as the headline implies.

"Given underlying fundamentals were in-line, we think the -11% move is overdone," Morgan Stanley wrote. "But it's hard to argue for a meaningful re-rating until we see positive organic estimate revisions."

That's not a bullish statement. It's a holding pattern. The firm kept its buy-equivalent rating and trimmed its price target to $36 from $37. The average 12-month target across 17 analysts tracked by TheStreet sits at $29, well below where the firm stands.

What this says about the rest of retail

Chewy is a useful canary because its customers are genuinely loyal, and its products cover a spectrum from discretionary (toys, treats) to near-necessity (prescription food, medication). When even that customer base starts trimming, it signals something real about the state of household budgets, not a panic, but a quiet, deliberate recalibration.

Morgan Stanley's bet is that the healthcare side of Chewy's business, veterinary services and prescription products, will provide a floor. Those customers are stickier, those relationships run deeper, and those margins are higher than commodity pet food. Chewy's expansion into vet clinics is the strategic pivot the company is making against the treat-cession. Whether it's enough to move the stock depends on something the analysts say they're waiting for: evidence, not reassurance, that organic growth can turn back up.

Chewy is down nearly 40% over the past year. For anyone who bought five years ago, the loss is closer to 72%.